Results 11 to 20 of about 5,732 (211)

Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia

Frontiers in Immunology, 2023
The application of immunotherapies such as chimeric antigen receptor (CAR) T therapy or bi-specific T cell engager (BiTE) therapy to manage myeloid malignancies has proven more challenging than for B-cell malignancies. This is attributed to a shortage of
Gianna M. Branella, Gianna M. Branella, Gianna M. Branella, Jasmine Y. Lee, Jasmine Y. Lee, Jasmine Y. Lee, Jennifer Okalova, Jennifer Okalova, Jennifer Okalova, Kiran K. Parwani, Kiran K. Parwani, Kiran K. Parwani, Jordan S. Alexander, Jordan S. Alexander, Raquel F. Arthuzo, Raquel F. Arthuzo, Raquel F. Arthuzo, Andrew Fedanov, Andrew Fedanov, Bing Yu, David McCarty, Harrison C. Brown, Shanmuganathan Chandrakasan, Shanmuganathan Chandrakasan, Brian G. Petrich, Christopher B. Doering, Christopher B. Doering, Christopher B. Doering, H. Trent Spencer, H. Trent Spencer, H. Trent Spencer   +30 more
doaj   +1 more source

The landscape of bispecific T cell engager in cancer treatment

Biomarker Research, 2021
T cell-based immunotherapies have revolutionized treatment paradigms in various cancers, however, limited response rates secondary to lack of significant T-cell infiltration in the tumor site remain a major problem. To address this limitation, strategies
Shujie Zhou, Mingguo Liu, Fei Ren, Xiangjiao Meng, Jinming Yu   +4 more
doaj   +1 more source

Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers

Frontiers in Immunology, 2023
T cell engagers, a category of T cell-retargeting immunotherapy, are rapidly transforming clinical cancer care. However, the lack of tumor-specific targets poses a significant roadblock for broad adaptation of this therapeutic modality in many ...
Even Walseng, Bo Wang, Chunning Yang, Pooja Patel, Chihao Zhao, Hanzhi Zhang, Peng Zhao, Yariv Mazor   +7 more
doaj   +1 more source

Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity

Communications Biology, 2021
Mandrup et al. describe a panel of recombinant albumin fusions, engineered with different affinities to the human neonatal Fc receptor to program the half-life extension of a bispecific (EGFR/CD3) T-cell engager.
Ole A. Mandrup, Sui Ching Ong, Simon Lykkemark, Anders Dinesen, Imke Rudnik-Jansen, Niels Frederik Dagnæs-Hansen, Jan Terje Andersen, Luis Alvarez-Vallina, Kenneth A. Howard   +8 more
doaj   +1 more source

Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins

Frontiers in Immunology, 2022
Despite the availability of an effective prophylactic vaccine, 820,000 people die annually of hepatitis B virus (HBV)-related liver disease according to WHO.
Bilge Debelec-Butuner, Bilge Debelec-Butuner, Oliver Quitt, Sophia Schreiber, Frank Momburg, Karin Wisskirchen, Karin Wisskirchen, Ulrike Protzer, Ulrike Protzer   +8 more
doaj   +1 more source

CD3‐T‐cell‐engager (TCE) therapies to overcome solid tumors: Beyond BiTEs

MedComm – Biomaterials and Applications, 2022
CD3‐T‐cell‐engager (TCE) therapies, such as bispecific T‐cell engagers (BiTEs), have achieved extraordinary success in treating hematological malignancies and have shown therapeutic effects comparable with those of chimeric antigen receptor (CAR)‐T ...
Jiali Zhang, Qianqian Guo, Quan Wang, Yourong Duan   +3 more
doaj   +1 more source

Progress of research on PD-1/PD-L1 in leukemia

Frontiers in Immunology, 2023
Leukemia cells prevent immune system from clearing tumor cells by inducing the immunosuppression of the bone marrow (BM) microenvironment. In recent years, further understanding of the BM microenvironment and immune landscape of leukemia has resulted in ...
Huizhen Cao, Tianyu Wu, Xue Zhou, Shuyang Xie, Hongfang Sun, Yunxiao Sun, Youjie Li   +6 more
doaj   +1 more source

T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC

Molecular Therapy: Oncolytics, 2017
The outcome for advanced stage hepatocellular carcinoma (HCC) remains poor, highlighting the need for novel therapies. Genetically modified mesenchymal stem cells (MSCs) are actively being explored as cancer therapeutics due to their inherent ability to ...
Arpad Szoor, Abishek Vaidya, Mireya Paulina Velasquez, Zhuyong Mei, Daniel L. Galvan, David Torres, Adrian Gee, Andras Heczey, Stephen Gottschalk   +8 more
doaj   +1 more source

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin

OncoImmunology, 2023
Mesothelin (MSLN) is an attractive immuno-oncology target, but the development of MSLN-targeting therapies has been impeded by tumor shedding of soluble MSLN (sMSLN), on-target off-tumor activity, and an immunosuppressive tumor microenvironment.
Daniel Snell, Tea Gunde, Stefan Warmuth, Bithi Chatterjee, Matthias Brock, Christian Hess, Maria Johansson, Alexandre Simonin, Fabio Mario Spiga, Christopher Weinert, Niels Kirk, Nicole Bassler, Lucia Campos Carrascosa, Naomi Flückiger, Robin Heiz, Sandro Wagen, Noreen Giezendanner, Alessandra Alberti, Yasemin Yaman, Dana Mahler, Dania Diem, Peter Lichtlen, David Urech   +22 more
doaj   +1 more source

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma

OncoImmunology, 2022
B cell lymphoma therapy has been transformed by CD19-targeting cellular therapeutics that induce high clinical response rates and impressive remissions in relapsed and refractory patients.
Lihe Su, Lan Wu, Roy R. Lobb, Paul D. Rennert, Christine Ambrose   +4 more
doaj   +1 more source